A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- at least 16 years old - immunocompromised or body is unable to fight off infection - have lesions that can been seen in order to determine if they are healing - willing to use highly effective birth control - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- history or current evidence of gastrointestinal malabsorption - on hemodialysis for any reason and end stage renal disease (ESRD) - women who are pregnant or breastfeeding - unable to communicate with study staff

Conditions & Interventions

Conditions:
Rare Diseases, Infectious Diseases
Keywords:
Clinics and Surgery Center (CSC), Herpes, Herpes Simplex Virus, HSV Infection

More Information

Description: The purpose of this research study is to look at the safety and effectiveness of pritelivir given orally (by mouth for a maximum of 42 days) for people with an impaired immune system who have recurrent lesions caused by the form of HSV that does respond to treatment with acyclovir.
Study Contact: Natalie Eichten - eicht024@umn.edu
Principal Investigator: Jo-Anne Young, MD
IRB Number: STUDY00020605